12/5
03:27 am
abbv
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer [Yahoo! Finance]
Low
Report
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer [Yahoo! Finance]
12/3
04:54 pm
abbv
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript [Seeking Alpha]
12/2
09:36 am
abbv
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers [Yahoo! Finance]
Low
Report
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers [Yahoo! Finance]
12/2
08:15 am
abbv
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Low
Report
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
12/1
06:01 am
abbv
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating [Seeking Alpha]
Low
Report
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating [Seeking Alpha]
12/1
04:00 am
abbv
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
Low
Report
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
11/30
09:29 am
abbv
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 [Yahoo! Finance]
Low
Report
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 [Yahoo! Finance]
11/30
03:33 am
abbv
Low
Report
11/28
07:01 am
abbv
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
Low
Report
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
11/25
09:30 am
abbv
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
Low
Report
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
11/24
08:00 am
abbv
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
11/19
12:12 am
abbv
Is AbbVie's 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? [Yahoo! Finance]
Low
Report
Is AbbVie's 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? [Yahoo! Finance]
11/18
03:57 pm
abbv
AbbVie Stock Falls 4% -- What Investors Need to Know [Yahoo! Finance]
Low
Report
AbbVie Stock Falls 4% -- What Investors Need to Know [Yahoo! Finance]
11/18
01:23 pm
abbv
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Low
Report
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
11/18
12:47 pm
abbv
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Low
Report
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
11/17
07:10 am
abbv
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer [Yahoo! Finance]
Low
Report
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer [Yahoo! Finance]
11/14
10:08 pm
abbv
3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy” [Yahoo! Finance]
Low
Report
3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy” [Yahoo! Finance]
11/14
04:33 pm
abbv
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript [Seeking Alpha]
Low
Report
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript [Seeking Alpha]
11/14
12:51 pm
abbv
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer [Yahoo! Finance]
Low
Report
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer [Yahoo! Finance]
11/14
12:30 pm
abbv
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Low
Report
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
11/14
07:50 am
abbv
AbbVie (NYSE:ABBV) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
AbbVie (NYSE:ABBV) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
11/13
09:53 am
abbv
AbbVie (NYSE:ABBV) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $280.00 price target on the stock.
Low
Report
AbbVie (NYSE:ABBV) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $280.00 price target on the stock.
11/13
09:30 am
abbv
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month [Yahoo! Finance]
Low
Report
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month [Yahoo! Finance]
11/13
08:30 am
abbv
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
Low
Report
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
11/12
09:36 am
abbv
AbbVie (ABBV) Surged Following Strong Results and Increased Guidance [Yahoo! Finance]
Low
Report
AbbVie (ABBV) Surged Following Strong Results and Increased Guidance [Yahoo! Finance]